Highest-materiality recent filing
CERo Therapeutics issues $500K convertible note to Keystone Capital at 10% interest
Initial purchase price $400,000; principal face value $500,000; up to $1M aggregate available.
Issued to Keystone Capital Partners a convertible note with purchase price $350,000 and face value $437,500.
Issued convertible promissory note to Keystone Capital Partners; purchase price $750,000, principal face value $937,500.
Issued $937,500 convertible note to Keystone Capital Partners at $750,000; 10% interest, matures July 2027, convertible at discount to market.
No cytokine release syndrome (CRS) or ICANS observed despite CD28 costimulatory domain and measurable cell expansion.
Nasdaq Listing Council affirms delisting of CERo Therapeutics securities
On Jan 29, 2026, the Nasdaq Listing and Hearing Review Council upheld the Panel's Oct 29, 2025 decision to delist CERo common stock and warrants.
First cohort completed DLT period with no CRS, ICANS, or treatment-related AEs reported.
CERO stockholders approve reverse stock split (1:40–1:150) and 32M share increase to equity plan
Reverse stock split ratio set by board at not less than 1:40 or more than 1:150; approved with 8,012,563 for, 2,287,082 against.
CERO Therapeutics enters new equity line for up to $14.6M from Keystone Capital
Company entered a new Common Stock Purchase Agreement with Keystone Capital for up to $14,591,939 of common stock.
Nasdaq Panel denies CERo Therapeutics continued listing; stock to suspend Oct 31
Shares of CERO common stock will be suspended from Nasdaq at open of trading on October 31, 2025.
CERo Therapeutics closes $2.25M initial closing of Series E preferred stock financing, total $7M
Initial closing of 3,816 Series E preferred shares raised $2.25M gross proceeds on Oct 16, 2025.
CERo Therapeutics raises up to $7M via Series E convertible preferred private placement
Initial closing of ~$1.8M; Series E convertible at $1,000 stated value, conversion price $4.1625 per share.
CERO Therapeutics updates investor presentation with no material new disclosures
Company furnished updated corporate presentation dated September 2025 as Exhibit 99.1, intended for investor meetings.
CERo Therapeutics receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia
FDA granted Fast Track Designation for CER-1236 in AML, adding to existing Orphan Drug Designation.
CERo Therapeutics receives Nasdaq delisting notice for equity shortfall, appeals
Nasdaq staff determined company fails minimum $2.5M stockholders' equity requirement for continued listing.
CERO Therapeutics closes additional $397,600 private placement of Series D Preferred Stock
Issued 497 shares of Series D convertible preferred stock for gross proceeds of approximately $397,600.
CERo Therapeutics enters new common stock purchase agreement for up to $17.5M with Keystone Capital
New Purchase Agreement allows CERo to issue and sell up to $17,490,897 of common stock to Keystone Capital, minus any additional proceeds from prior November deal after June 30, 2025.
CERo Therapeutics regains Nasdaq bid price compliance; delisting hearing canceled
On July 7, 2025, Nasdaq determined CERo regained compliance with the $1.00 minimum bid price rule.
CERo Therapeutics raises $1.85M via Series D preferred stock; adds new institutional investors
Closed additional closing of 2,315 shares of Series D convertible preferred stock for gross proceeds of ~$1,852,000.
FDA grants Orphan Drug Designation to CERo's CER-1236 for AML treatment
FDA Orphan Drug Designation granted to CER-1236 for acute myeloid leukemia (AML).
CERo Therapeutics receives Nasdaq bid price deficiency notice; effects 1-for-20 reverse split
Received Nasdaq notice on June 11, 2025: bid price below $1.00 for 30 consecutive business days (Apr 25–Jun 9).
CERo Therapeutics announces 1-for-20 reverse stock split effective June 13, 2025
Outstanding shares reduced from ~10,321,839 to ~516,092; par value $0.0001 unchanged.
CERo Therapeutics raises ~$750k in Series D financing; first-in-human dosing under way
Gross proceeds from additional closing ~$750k; total Series D up to $8M with $5M previously issued.
CERo Therapeutics enters new employment agreements with CEO and CFO effective June 4, 2025
CEO Chris Ehrlich receives base salary of $480,000/year and a one-time performance bonus of 50% of base salary.
CERO Therapeutics shareholders approve 1:20 reverse stock split, increase share reserve by 2M shares
Reverse stock split ratio set at 1:20, effective 12:01 a.m. ET on June 10, 2025, subject to regulatory processes.
the Company agreed to employ Mr. Ehrlich as the Company’s Chief Executive Officer as of and from June 4, 2025.
the Company agreed to employ Mr. Kucharchuk as the Company’s Chief Financial Officer as of and from June 4, 2025.
Max materiality 0.95 · Median 0.65 · Most common event other_material